Featured Articles

51. Bringing Allogeneic Cell Therapy To Patient Care 11/1/2022

    Bringing allogeneic cell therapy to patient care will require flexible, closed, and automated solutions to support the treatment options and increasing scale of the industry.

52. Strategies To Overcome Delays In The Development Of Genomic Medicines 10/13/2022

    Learn how optimizing LNPs can help overcome drug-delivery challenges, unlocking potential new genomic medicines in a shorter time.

53. Optimizing Capture And Polishing Steps In An rAAV Purification Process 10/13/2022

    We adapted an affinity capture step for rAAV2 and rAAV5, followed by a polishing step with rAAV5 to improve the yield of rAAV full capsids.

54. Developing A Scalable RNA-LNP Drug Product For Clinical Translation 9/22/2022

    Accelerate essential process development activities with instrumentation solution allowing for highly reproducible and scalable production of RNA-LNPs.

55. Optimizing Lipid Formulations For Targeted RNA-LNP Applications 9/13/2022

    Learn about the considerations and challenges of using ionizable lipids, including the 5 types of lipids used for RNA delivery.

56. Process Development Considerations For RNA-LNP Therapeutics 9/13/2022

    Here, we highlight three important process considerations across the RNA-LNP manufacturing workflow which includes limit size behavior, in-line dilution and downstream tangential flow filtration (TFF).

57. Key Stages In mRNA-Based Therapeutic Development 9/13/2022

    Learn how planning a product development strategy early on with a technology partner who has deep expertise and technical knowledge of genomic medicines can address uncertainties from the outset.

58. Vanderbilt Moves Towards A Paperless Cell Therapy Process 8/8/2022

    The future of cell-therapy systems is here, so learn the importance of patience when implementing a paperless system today.

59. Perfusion Filter Improves Cell Retention In Xuri Cell Expansion System 7/21/2022

    A new 1.2 μm pore size filter was validated for use in the Xuri Cell Expansion System W25, which decreased T cell loss, ultimately leading to higher T cell retention in the Xuri brand Cellbag bioreactor.

60. Tips For Successfully Scaling Your cGMP Manufacturing 6/23/2022

    What are the specific obstacles to expanding manufacturing capacity? Cell therapy industry leaders share what to look for in a solutions provider and recommendations for navigating your road ahead.